Skip to main content
. 2014 Jun 20;307(3):L261–L272. doi: 10.1152/ajplung.00345.2013

Fig. 8.

Fig. 8.

Relative mRNA expression in lung homogenates after early concurrent treatment (A–H) of monocyte chemoattractant protein 1 (MCP1; A), chemokine-induced neutrophilic chemoattractant-1 (CINC1; B), plasminogen activator inhibitor 1 (PAI-1; C), angiotensin receptor type 1a (AT1a; D), AT2 (E), MAS oncogene receptor (MAS; F), angiotensin converting enzyme (ACE; G), and angiotensin converting enzyme 2 (ACE2; H) on day 10 in RA pups injected daily with saline (open bars) or PD123319 (0.1 mg·kg−1·day−1; hatched bars) and O2-exposed pups injected daily with saline (solid bars) or PD123319 (shaded bars). Relative mRNA expression of Mas-related receptor, type D (MrgD or alamandine receptor) in lung, spleen, thymus, ovary, kidney, brain, heart, liver, and testis (I). Values are expressed as means ± SE (N = 8). *P < 0.05 and ***P < 0.001 vs. age-matched O2-exposed controls. ΔΔP < 0.01 and ΔΔΔP < 0.001 vs. RA controls.